Huaxia Yingtai

华夏英泰

Huaxia Yingtai

Biotech/Healthcare

Founded in 2018 under the leadership of globally renowned immunologists, Huaxia Yingtai aims to develop next-generation cell therapy products through its proprietary STAR-T TCR-T technology platform, addressing solid tumors, hematological malignancies, and autoimmune diseases and becoming a leading…

Latest round: Series C (2026)

Source: ChinaBulls — chinabulls.com

Last updated 2026-07-06